In-vitro maturation: patient selection and results Aygul Demirol Assoc Prof, Medical Director GURGAN CLINIC IVF Center, Ankara-Turkey.

Slides:



Advertisements
Similar presentations
Ovulation induction TAQI Consultant OB/GYN,Infertility,IVF
Advertisements

In Vitro Fertilization
 OHSS is a serious, potentially life- threatening, iatrogenic complication of “controlled” ovarian stimulation.  To optimize the ovarian response without.
ART-IVF: the Long and Short of it Professor Ernest Hung Yu NG Department of Obstetrics & Gynaecology The University of Hong Kong.
IOGENESI Centro di Medicina della Riproduzione B Laboratory aspects of IVM DAL CANTO MARIABEATRICE BIOGENESI REPRODUCTIVE MEDICINE CENTER, ISTITUTI CLINICI.
Elonva in poor responders
Hananel Holzer, MD Medical Director, MUHC Reproductive Center McGill University Health Center Director, REI Division, Dept. of Obstetrics & Gynecology.
Case Report: The Birth of a Normal Healthy Baby from Blastocysts Frozen and Thawed Twice L. Keith Smith, Ellen H. Roots and M. Janelle Odom Dorsett The.
Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.
LIFE AFTER NEW IVF LEGISLATION IN TURKEY Hakan Ozornek, MD EUROFERTIL Istanbul.
INDIVIDUALIZED IVF TREATMENT
History and Fundamentals of Oocyte Maturation in Vitro
In Vitro Fertilisation (IVF) IVF enables fertilisation, outside the body, in a culture dish.
The Women’s Clinic 婦產科中心 New Concept of Controlled Ovarian Stimulation in IVF Dr. Milton Leong MDCM DSc (McGill) Director, IVF Center, HKSH Specialist.
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
In Vitro Fertilization by Ms. Mann. Assessment Statements Outline the process of in vitro fertilization (IVF) Discuss the ethical issues associated.
Insulin sensitizing agents use in pregnancy and as therapy in PCOS
IVM is ready as a treatment for PCOS patients
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF Jessica B Spencer 1*, Aimee S Browne 1, Susannah D Copland.
Comparison Of Letrozole And Clomiphene Citrate Saima Ahmad MRCOG Riaz Medical Center Sharjah. UAE Objectives Conclusions Competing Interest References.
Selective Single Embryo Transfers: A Preliminary Study L. Keith Smith, Ellen H. Roots and M. Janelle Odom Dorsett The Centre for Reproductive Medicine,
Does exogenous LH activity influence the outcome in IVF and not in ICSI cycles? Peter Platteau, Johan Smitz, Carola Albano, Per Sørensen Joan-Carles Arce.
Safety and efficacy of FSH drugs in ART for polycystic ovarian disease M. Aboulghar Cairo, Egypt.
Objectives Polycystic ovary syndrome (PCOS) is characterized by chronic anovulation and hyperandrogenism and affects approximately 5–10% of women of reproductive.
Hong Kong Sanatorium & Hospital, China
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
Planning of GnRH antagonist cycles
Treatment Options for Infertility
CONCEPTION, DEVELOPMENT, AND BIRTH CHAPTER 46 (AP BOOK)
Hakan Özörnek EUROFERTIL IVF Center Turkey.  No or minimal stimulation  Low cost  Less monitoring  Less side effects (OHSS)  Acceptable pregnancy.
The Women ’ s Clinic 婦產科中心 IVM/IVF in PCOS (PCO-Like Ovaries) Milton Ka Hong Leong MDCM DSc(McGill) FRCS(C) FRCOG FACOG FHKCOG Director, IVF Centre HK.
Dr. Milton Leong Director
The Effect of Bromocriptine-Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: a Randomized Clinical Trial.
TEMPLATE DESIGN © IMPACT OF SEXUAL ABSTINENCE DURATION ON ICSI OUTCOME May Kew Loke and Pak Seng Wong Sunfert International.
SL ‘00 Antagonists in patients with previous poor ovarian response Antagonists in patients with previous poor ovarian response Geoffrey H Trew Consultant.
Agonist vs Antagonist Dr. Milton Leong.
Aline de Cássia Azevedo (a,b) ; Fernanda Coimbra Miyasato (b) ; Litsuko S. Fujihara (b), Maria Cecília R.M. Albuquerque (b), Ticiana V. Oliveira (b), Luiz.
Results 13 papers Heterogeneity of morphokinetic and conditions (culture media, mode of fertilization, day of ET)
Natural IVF/ET - treatment success Neda Smiljan Severinski Marko Gospić.
Methods of assisted reproduction MUDr.Jitka Řezáčová ÚPMD, Praha 4, Podolí.
Testicular sperm retrieval by fine needle aspiration and ICSI treatment for infertile men with azoospermia: Results of a two- years experience at Prince.
Selecting sperm for ICSI - IMSI Allan Pacey University of Sheffield Sheffield Teaching Hospitals.
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
Luteal coasting post GnRH agonist trigger
Clinical Trials – Human Gonadotropin Drug Products A Regulatory Perspective Shelley R. Slaughter, M.D., Ph. D. Reproductive Medical Officer Team Leader.
IVM IVF/ICSI nin YERİNİ ALACAK MI ?
Methods Interleukim6,Interleukin 1 ,Estradiol and Testosterone Concentrations in Serum and Follicular Fluid of females with stimulated and non-stimulated.
DAY 6 BLASTOCYST TRANSFERS INCREASE THE PREGNANCY, IMPLANTATION AND LIVE BIRTH RATES COMPARED TO DAY 5 BLASTOCYST TRANSFERS IN HUMAN IVF-ET L.K. Smith,
Reproductive biology 1/ Reproductive organs and hormonal control 2/ The biology of fertility control 3/ Ante-natal and post-natal screening.
Biology of Fertility Control
(Miz Medi Hospital) Jung-Hyun Cho, M.D. (Miz Medi Hospital) Minimal Ovarian Stimulation.
IVF TROUBLESHOOTING ( Clinical Perspective) Malvin Emeraldi M. Luky, Dianing ASR,Muchsin J Family Fertility Center, RSIA Family Fatmawaty Hospital Jakarta,
ART & Fertility Massage Clare Blake N.D. Fertility Massage Therapy & Training.
Fertility Facts Definition:unprotected sex for one year, not pregnant
An analysis of 2,566 cycles Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: An analysis of 2,566.
Welcome.
IN VITRO FERTILIZATION
Endometrial biopsy in subfertile women undergoing intrauterine insemination (IUI) cycles improves pregnancy rates Tumanyan A, Tchzmachyan R, Grigoryan.
The timeline shows the day of menstrual cycle for a typical patient
Menstrual Cycle and Fertilization
Facilitator: Pawin Puapornpong
IN VITRO FERTILISATION
ultrasound of the female pelvis
Mohamed Elmahdy MD. Lecturer Obs. Gyn. Alexandria University Egypt
Fertility Noadswood Science, 2016.
Polycystic ovarian syndrome Obesity and Insulin resistance
Pregnancy outcomes after assisted reproductive procedures of embryos derived from affected and unaffected ovaries among women with small unilateral endometriomas.
Supplemental Table 2. Reproductive outcomes
LIFE GLOBAL MEDIA RESULTS Ege UNİVERSİTY Experience
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
Presentation transcript:

In-vitro maturation: patient selection and results Aygul Demirol Assoc Prof, Medical Director GURGAN CLINIC IVF Center, Ankara-Turkey

In-vitro maturation (IVM) Immature oocyte retrieval and subsequent oocyte maturation in vitro without any ovarian stimulation Immature oocyte retrieval and subsequent oocyte maturation in vitro without any ovarian stimulation

IVM (in-vitro maturation) In 1991, Cha et al. reported a pregnancy from IVF with oocytes obtained from ovariectomy specimens and matured in culture (healthy triplet girls) (Cha KY, Fertil Steril 1991)

Trounson et al. reported the birth of a normal baby with IVM of immature oocytes from a polycystic ovary syndrome (Trounson Fertil Steril 1994) IVM (in-vitro maturation)

There have been more than 1000 births of babies with IVM procedures, including in patients with PCOS (Chian RC) BUT, IVM has not become mainstream in IVF, with ovulation induction cycles with oocyte retrieval of mature (MII) oocytes still the highly favored protocol.

Why IVM ? Reduced cost Reduced cost Avoiding OHSS Avoiding OHSS Simplification of treatment compared with conventional IVF-ET

IVM Indications PCOS PCOS High responders High responders IVF/IVM IVF/IVM Fertility preservation Fertility preservation Donation cycles Donation cycles Delayed responders Delayed responders Male infertility Male infertility Poor responders Poor responders

2-12 mm follicles

In general clinical pregnancy rate 30-35% clinical pregnancy rate 30-35% implantation rate 10-15% implantation rate 10-15% (R.C. Chian RBM Online, 2004)

IVM low implantation rates when compared to conventional stimulated cycles. low implantation rates when compared to conventional stimulated cycles. –asynchrony in the cytoplasmic and nuclear maturation of the oocyte –asynchrony in the endometrium –culture conditions

IVM is based on the treatment of Two main groups of patients Two main groups of patients –With PCO ( –With PCO (have irregular, mostly anovulatory cycles and are at increased risk for OHSS because of their higher sensitivity to gonadotropins) –With normal ovaries ( –With normal ovaries (may wish to avoid the side-effects of hormone injections)

How to maximize IVM results by optimizing clinical management Patient selection criteria-best candidates Patient selection criteria-best candidates –Under 35 years of age –PCO/PCOS

Patient management-I Baseline TV-USG (day 2, 3) Second USG (between day 6 and day 9) (for follicular and endometrial assessment) HCG priming 36 hours prior to egg collection

Patient management-II IVM ovum aspiration needle, single or double lumen, 19 G, 35 cm IVM ovum aspiration needle, single or double lumen, 19 G, 35 cm Aspiration pressure mmHg Aspiration pressure mmHg All visible follicles are aspirated All visible follicles are aspirated

Patient management-III Priming with FSH or HMG ? Priming with FSH or HMG ? Priming with HCG ? Priming with HCG ?

FSH Priming Results are conflicting Results are conflicting Potential benefits: Potential benefits: –Larger ovarian size –Easier retrieval –Higher E2 levels –More maturational competence May lead to improved endometrial priming

HCG Priming Theoretically HCG priming Theoretically HCG priming –Promote invitro maturation –Improve pregnancy rates However the exact mechanism of HCG on small follicles is still unclear

HCG Priming First prospective study First prospective study Chian et al. (2000) Increased oocyte maturation Increased oocyte maturation High clinical pregnancy rate High clinical pregnancy rate ( 36 %)

hCG Priming In-vitro maturation rate is faster in oocytes obtained from hCG primed IVM oocytes. In-vitro maturation rate is faster in oocytes obtained from hCG primed IVM oocytes. (Chian et al.,Human Reprod,2000 ; Son et al., RBM Online,2006) (Chian et al.,Human Reprod,2000 ; Son et al., RBM Online,2006) - Hastens the the oocyte maturation in-vitro - Hastens the the oocyte maturation in-vitro - Makes the oocyte retrieval easier - Makes the oocyte retrieval easier Mature oocyte on the day of retrieval is higher Mature oocyte on the day of retrieval is higher (Son et al.,Hum.Reprod,2002) (Son et al.,Hum.Reprod,2002) Higher fertilization,cleavage and blastocyt development rates in IVM cycles Higher fertilization,cleavage and blastocyt development rates in IVM cycles Number of good quality blastocysts higher (40% vs 23.3%) (Son et al.,RBM Online,2008) Number of good quality blastocysts higher (40% vs 23.3%) (Son et al.,RBM Online,2008)

Lab management-I Lab management-I Determination of cumulus-oocyte complexes (COCs) (special sliding technique-after using cell strainer) Determination of cumulus-oocyte complexes (COCs) (special sliding technique-after using cell strainer) The immature COCs are incubated in culture dish containing 1 ml oocyte maturation medium supplemented with a final concentration of 75 mIU/ml FSH and 75 mIU/ml LH The immature COCs are incubated in culture dish containing 1 ml oocyte maturation medium supplemented with a final concentration of 75 mIU/ml FSH and 75 mIU/ml LH for SAGE medium for SAGE medium

For MediCult medium, preincubation in LAG medium (2-3 hours) For MediCult medium, preincubation in LAG medium (2-3 hours) Transferring into IVM final maturation medium (9 ml IVM medium is added 1 ml patient serum, 10 µ l pregnyl, 100 µ l FSH) Transferring into IVM final maturation medium (9 ml IVM medium is added 1 ml patient serum, 10 µ l pregnyl, 100 µ l FSH) Lab management-II Lab management-II

Stripping oocytes 24 hours after culture Stripping oocytes 24 hours after culture Twenty for hours after maturation additional 24 hours for immature COCs Twenty for hours after maturation additional 24 hours for immature COCs Mature oocytes are subjected to ICSI Mature oocytes are subjected to ICSI Embryo maintenance medium for SAGE Embryo maintenance medium for SAGE ISM1 for MediCult ISM1 for MediCult Lab management-III Lab management-III

Endometrial priming 17-β-oestradiol starts on the day of OPU (2 mg orally, three times daily and continue until pregnancy test) 17-β-oestradiol starts on the day of OPU (2 mg orally, three times daily and continue until pregnancy test) Two days after OPU, intravaginal progesterone suppositories mg, daily and continue until pregnancy test) Two days after OPU, intravaginal progesterone suppositories mg, daily and continue until pregnancy test)

Clinical outcome for PCO/PCOS Jurema MW. Fertil Steril 2006;86:1277–91.

Clinical outcome for normal ovaries Jurema MW. Fertil Steril 2006;86:1277–91.

Pregnancies and deliveries after transfer of human blastocysts derived from in vitro matured oocytes in IVM ( PCO(S) ) (Blastocyst vs cleavage ET)

The abortion rate, gestational age and birth weight at delivery, and obstetric complications of pregnancies conceived by IVM-ET in women with PCOS were comparable with those of other women with PCOS being treated by conventional IVF-ET (Fertil Steril, 2005)

CONCLUSION: Compared with IVF and ICSI, IVM is not associated with any additional risk. (Obstet Gynecol 2007;110:885–91)

Outcome of the IVM cycles (sept 2005-jan 2010) GURGAN CLINIC IVF Center Ankara, Turkey

n%mean Mean age30.2 Cycles321 Cycles with oocytes Oocytes retrieved h maturation Oocytes reaching MII Oocytes fertilized(2PN) Embryos cleaved h maturation Oocytes reaching MII Oocytes fertilized (2PN) Embryos cleaved

n% mean transfer and outcome Cycles with embryo transfer Embryos transferred Biochemical pregnancies/transfer Clinical pregnancies/transfer Implantation rate 13.4 Ongoing pregnancies 41 Live birth16 Abortion rate2126.9

Immature oocyte after oocyte pick-up

Mature oocytes after denudation & ICSI

Fertilised (2 PN)oocytes

Cleavage stage (Day 2) embryos

Blastocyst stage (Day5)

PREGNANCIES IN TURKEY FOLLOWING IN VITRO OOCTYE MATURATION Aygul Demirol, Tamer Sari, Bagdagul Girgin, Erkin Kent, Suleyman Guven, Timur Gurgan 2007, GORM *Two women with history of infertility and PCOS underwent in vitro maturation (IVM) program without controlled ovarian hyperstimulation. The patients were primed with IU HCG 36 h before oocyte retrieval. Oocytes-cumulus masses were matured in IVM medium. The matured oocytes were fertilized by ICSI and embryo transfer was performed on day 3

accepted

IVM for a Second Chance Recent reports: Recent reports: Risk of OHSS Risk of OHSS Immature oocyte retriaval + IVM instead of cancellation 47 % CLINICAL PREGNANCY No OHSS Lim et al. Fertil Steril ,000 IU HCG Leading follicle = mm

Natural Cycle + IVM But natural cycle yields only 1 single follicle But natural cycle yields only 1 single follicle For other non dominant follicles For other non dominant follicles IVM may be an option Because IVM is possible even if the dominant follicle is selected Thornton 1998 Fertil Steril

Thank you for their help and support Ri-Cheng Chian, McGill Reproductive Center, Montreal, Canada Ri-Cheng Chian, McGill Reproductive Center, Montreal, Canada Mette Munk, Jyllinge, Denmark Mette Munk, Jyllinge, Denmark and others… and others…